Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-20-15
Credit Expiration Date: February-20-17

Faculty

Joel C. Marrs, PharmD, FNLA, BCPS (AQ Cardiology), BCACP, CLS
Associate Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
Aurora, CO

Laura V. Tsu, PharmD, BCPS, CGP
Assistant Professor, Pharmacy Practice
Midwestern University College of Pharmacy-Glendale
Glendale, AZ

Credit Hours

1.0 Contact Hour (0.1 CEU)

Medium

e-Monograph

Program Description

A CPE-certified online monograph with highlights from the American Society of Consultant Pharmacists workshop.


Nonvalvular atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and afflicts more than 3 million people in the United States. AF is an independent risk factor for ischemic stroke severity, recurrence, and mortality. AF is a disease predominantly of older adults: the median age for AF patients is 73 to 75 years. Although most AF-related strokes could be prevented with anticoagulation therapy, many patients with AF are not receiving appropriate evidence-based therapy for stroke prevention. The goal of this monograph is to give consultant pharmacists the tools to overcome barriers to the use of anticoagulation therapy for the prevention of stroke in older adults with AF.

NOTE: This activity was originally presented as a workshop on November 5, 2014, in conjunction with ASCP's Annual Meeting and Exhibition.

Program Developer/Facilitator


.

Target Audience

This activity is intended for consultant and senior care pharmacists as well as other pharmacists involved or interested in senior care pharmacy and the care of older patients with atrial fibrillation.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Determine when a patient with atrial fibrillation is at risk for stroke using evidence-based risk scoring assessments.
  2. Discuss the risk of stroke versus the risk of intracranial bleeding from anticoagulant therapy in patients with AF.
  3. Compare the benefits and risks of warfarin and direct-acting oral anticoagulant anticoagulant medications.
  4. Discuss reversal agents for non-warfarin anticoagulant medications that are currently under late-stage investigation.
  5. Describe a patient who should remain on warfarin therapy and a patient who should be considered for direct-acting oral anticoagulant therapy.
  6. Outline current evidence for prescribing aspirin for the prevention of stroke in patients with AF.

Disclosures

It is the policy of ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

Dr. Marrs: Nothing to disclose
Dr. Tsu: Nothing to disclose

ASCP:
Ms. Dechevalier has no relevant financial conflicts to disclose.
Dr. Baird has no relevant financial relationships to disclose.

MCM:
Ms. Sharp, MCM writer/editor, has no relevant financial conflicts to disclose.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity Number 0203-9999-15-005-H01-P, has been assigned 1.0 Contact Hour (0.1 CEU).

Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit.

Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test.

This activity will take approximately 1 hour to complete.

Commercial Support Statements

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer, Inc. and Daiichi Sankyo, Inc.

Instructions

There are no fees for participating in or receiving credit for this online educational activity. This activity is designed to be completed within the time designated on this page; pharmacists should claim only those credits that reflect the time actually spent in the activity.

  1. Review the intended audience, learning objectives, and author disclosures.
  2. Study the educational content online. Be sure to review both written and audio/slide content.
  3. Once completed, continue to post-test. Online, choose the best answer to each test question. To receive a statement of credit, you must receive a passing score as designated at the top of the test. In addition, you must also complete the Activity Evaluation.
  4. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers

Certificate Fee

$0.00

Disclaimer

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, American Society of Consultant Pharmacists, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Pfizer, Inc., or Daiichi Sankyo, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS